FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis

This study is testing whether adding fecal microbiome transplant (FMT) — transferring healthy gut bacteria from a donor — to standard first-line treatment (immunotherapy plus chemotherapy) improves outcomes for patients with advanced colon cancer that has spread to the liver and does not have a genetic mutation called MSS-type. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed advanced colon cancer with liver metastases - You have not yet received any cancer treatment - You are in good performance status (ECOG 0–1) - You have at least one measurable tumor - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have previously received treatment for colon cancer - You have autoimmune disease or connective tissue disease - You are pregnant or breastfeeding - You have serious organ dysfunction Talk to your doctor to see if this trial is right for you.